NuMat Medtech

We want people to smile

We are specialists in developing innovative surfaces of biomaterials for medical applications. Our R&D activities are focused on producing biomaterials for bone-anchored devices, like dental and orthopaedic implants surfaces, scaffolds and bone filling devices with improved and added functionalities.

As a result of this activity we have developed 4 bioactive implant surfaces with innovative and tailored functionalities.

About

NuMat Medtech is a biotech company located at the ParcBIT (Balearic Islands Innovation and Technology Park). Our main activity is the development of innovative biomaterials for bone-anchored devices like dental implants, orthopaedic prosthesis, scaffolds and bone filling devices for reconstruction and regeneration in bone.

NuMat Medtech is developing a pipeline of products consisting of the bioactive treatment of multifunctional implant surfaces, addressed to solve the main problems related to the use of these implants: reduction of infections and inflammation, tissue regeneration around the implant, modulation of the osseointegrative properties and reduction of the risk of rejection.

The company was formed as a consequence of the merger between Sanifit Medtech and NuMat Biomedical. Sanifit Medtech was a spin-off of Laboratoris Sanifit, leading company in the treatment of calcification disorders. NuMat Biomedical was created as a joint initiative of Numat AS (Norway) and Dr. Marta Monjo, Ph.D. in Molecular Biology with 10+ years of experience in research in biomaterials.

NuMat Biomedical and Sanifit Medtech started in 2013 a collaborative Project called PHYTECH, aimed to design and develop new materials for bone implants. This project was financed with an INNPACTO Project from the Spanish Ministry of Science and Innovation and with an Eurostars Project. After the finalization of the project, the two companies decided to join efforts to better use the synergies between them and created NuMat Medtech.

Leadership

Antonio Caldentey | CEO

Antonio is Chief Executive Officer of NuMat Medtech and managing partner of Invenzia Capital Investments. Since the beginning of 2017 he hold the position of Interim Manager of NuMat Medtech with the aim of defining the company's strategy, structuring the capacities that allow the development of the business and completing a Seed Round fundraising. Since November 2018 Antonio is CEO of NuMat and will be responsible to consolidate the company's business model and bring NuMat technologies to the market. In his position at Invenzia Capital, he has participated in numerous financing processes for start-ups in various fields, including ICTs for the tourism sector and Biotech. Antonio served as Senior Manager at ONEtoONE Corporate Finance from 2008 to 2018, working in M&A transactions in the sectors of tourism, healthcare and IT. He has participated in IPOs on the Mercado Alternativo Bursátil (MAB), sell and buy side mandates, financing for internationalization projects and refinancing processes in hospitality sector. Antonio holds BSc Degree in Business Administration and Management and Master in Business Administration (MBA) from ESADE (2006). Executive Program in Corporate Finance from ESADE (2008). Master's Degree in Economic-Financial Management by the Centro de Estudios Financieros - UDIMA (2017).

Marta Monjo, CSO

Marta is CSO and co-founder of NuMat Medtech. She served as Chief Executive Officer at NuMat Biomedical from 2008 to 2013, and from 2014 to 2016 as CSO. She was part of the executive commission of The Balearic Islands Biotechnology and Biomedical Cluster since its beginning until September 2013. She was partner of Corticalis AS (Norway) from 2008 to 2015. Marta has received several prizes for her entrepreneurship. Her research has resulted up to now in the publication of more than 60 research articles, more than 70 presentations to national and international conferences, and 4 patents. She has participated in 15 R&D projects (7 as main investigator) and 11 contracts with companies. Marta holds an MSc in Biology and MSc in Biochemistry, and earned her PhD from the University of the Balearic Islands, Spain, where she teaches nowadays as Contracted Lecturer. Moreover, she is the principal investigator of the group ‘Cell Therapy and Tissue Engineering’ at IUNICS-UIB, and coordinates de Area of Bioengineering and Experimental Surgery at the Instituto de Investigación Sanitaria de Palma (IdISPa).

Joana M. Ramis, Laboratory Director

Joana Maria is Laboratory Director and co-founder of NuMat Medtech. She served as R&D at NuMat Biomedical from 2009 to 2013, and from 2014 to 2016 as Chief Executive Officer. Joana Maria has received several prizes related to her scientific work and entrepreneur activity. Her research has resulted up to now in the publication of more than 40 research articles, more than 25 presentations to national and international conferences, and 2 patents. She has participated in 16 R&D projects (3 as principal investigator) and 4 contracts with companies. Joana Maria holds Bachelor degree in Pharmacy and in Biochemistry, and earned her PhD from the University of the Balearic Islands, Spain, where she teaches nowadays as Adjunct Lecturer.

Board of Directors

Joan Perelló, Chairman

Joan is Chairman at NuMat Medtech. He is also CEO and co-founder of Sanifit, where he has led several financing rounds at Sanifit totalling >€40m, including most recently a series raised Euro 37m. He served as Chief Scientific Officer at Sanifit from 2004 to 2013, and from 2009 to 2013 he pioneered the international development of Sanifit’s lead candidate, SNF 472, from academia to its clinical evaluation in patients suffering from calciphylaxis and ESRD. He is founder at Conceptio Biotech and President of the Balearic Cluster of Biotechnology and Biomedicine and Vice-Dean at the Official College of Chemists in the Balearic Islands, Spain. Joan has earned several research and innovation prizes, including the National Prize for the best Doctoral Thesis in Lithiasis, awarded by Ferrer Pharma in 2005. He is co-author of over 40 peer-reviewed international publications, co-inventor of 9 international patents, and has participated in over 30 research projects, half of which as Principal Investigator. Joan holds an MSc in Chemistry with first class honours, and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical and Clinical Chemistry as Adjunct Lecturer.

Bernat Isern, Board Member

Bernat is co-founder and currently CMC Project Manager, Grants Officer & QA at Sanifit. He has led several public funds projects, achieving a total amount higher than 7M€. He served at Sanifit as Chief Operation Officer from 2004 to 2012 and as Board Member from 2007 to 2014. He has extensive experience in the field of pathological calcifications and bioanalysis of inhibitors of crystallization, having been investigator in 26 research projects being the Principal Investigator in 7 of them and co-inventor of 8 international patents. He is also co-author of 30 scientific international publications and 30 congress communications. Bernat holds an MSc in Chemistry with first class honours, and earned his PhD from the University of the Balearic Islands, Spain, where he teaches Analytical Chemistry as Associate Professor. Since 2010, he is Vice-President of the Balearic Association of Biotechnology Companies

José Antonio Mesa, Board Member

Jose Antonio is the Chief Investment Officer at Caixa Capital Risc. He specializes in investment in drug development and medical devices. He currently serves on the Board of Directors at Medlumics, Stat Diagnostica, Laboratoris Sanifit, Genmedica, nLife Therapeutics and NuMat Medtech. He is responsible for the analysis, negotiation and structuring of processes in life science companies. Jose A. has more than 10 years of experience in the analysis of investment opportunities and specializes in the creation and early health sector companies. His experience began in the Department of Business Development at Genzyme Corporation, a company specializing in the development and sale of drugs for orphan diseases. He later joined the Technology Portfolio team at Genoma España, a public sector foundation that promotes technology development, knowledge transfer and innovation in the biotechnology sector. Jose Antonio holds a degree in Biology (Genetics) and a Masters in Corporate Finance from the U. Complutense, Madrid (UCM), MBA and PDD from IESE.

Scientific Advisory Board

Staale Petter Lyngstadaas

Professor and Chairman at Department of Biomaterials, and Dean of Research at the Faculty of Dentistry, University of Oslo (Norway). Research director of Biora AB (Sweden) from 1997 to 2001. Co-inventor of Emdogain, Emdogain Gel and PrefGel (Straumann AG, Switzerland) for the dental market and Xelma (Mölnlycke Health Care AB, Sweden) for cronic wound care market. Co-founder and CEO of Corticalis AS (Norway). University of Oslo – Birkeland Innovation Award 2009. His Majesty King Olav V gold medal for excellence in science 1997.

Jan Eirik Ellingsen

Professor and Chairman at Department of Prosthetics and Oral Function, Faculty of Dentistry, University of Oslo (Norway). Co-inventor of Osseospeed™ dental implant (Dentsply Sirona Inc, USA); Solidox Hvite Tenner and Solidox Frisk Pust toothpastes (Lilleborg AS, Norway); and SB12 mouthwash (former Solidox Frisk Pust mouthwash) (SB12 AB, Sweden). Co-founder and Chairman of the Board of Corticalis AS (Norway). Member of Scientific advisory board Astra Tech Implants. William R. Laney award 2006. University of Oslo – Birkeland Innovation Award 2009.

Maria Luisa González, Universidad de Extremadura

Professor of Applied Physics and leader of the research groups of Surfaces and Interfacial Phenomena in the University of Extremadura, and the Microbial Adhesion Group in the CIBER-BBN. She is responsible of the Surface Characterization and Calorimetry Unit of the ICTS NANBIOSIS. She has more than 130 publications in leading international journals and has been Principal Investigator in a number of competitive grants. She is active as reviewer for a high number of journals in different fields and has acted as an expert for a number of research agencies in different countries. She has several collaborations with companies dedicated to the manufacture of implants.

Pipeline

NM_971 - Bioactive osteointegrative surface for compromised patients (e.g. osteoporotic or diabetic)

Biocompatible and bioactive metal surfaces coated with UV-activated 7-Dehydrocholesterol (7-DHC) that stimulate bone formation. 7-DHC, the precursor of vitamin D, once activated with UV-light is used by the cells to locally produce active vitamin D after implantation. For use in bone implants, especially in compromised patients (e.g. osteoporotic or diabetic).

Key publications:

Satué, M. et al. (2013). UV photoactivation of 7-dehydrocholesterol on titanium implants enhances osteoblast differentiation and decreases Rankl gene expression. Acta Biomater 9(3):5759-70.
Satué, M. et al. (2014) Cholecalciferol synthesized after UV-activation of 7-dehydrocholesterol onto titanium implants inhibits osteoclastogenesis in vitro. Journal of Biomedical Materials Research Part A 103 (7): 2280-2288.
Satúe, M. et al. (2016). UV-activated 7-dehydrocholesterol coated titanium implants promote differentiation of human umbilical cord mesenchymal stem cells into osteoblasts. Journal of Biomaterials Applications 30( 6): 770-779.
Satué, M. et al. (2016). Improved human gingival fibroblast response to titanium implants coated with UV-irradiated vitamin D precursor and vitamin E. Journal of Periodontal Research 51:342-349.
Satué, M. et al. (2016).Titanium implants coated with UV irradiated vitamin D precursor and vitamin E: in vivo performance and coating stability. Clinical Oral Implant Research. doi: 10.1111/clr.12815

NM_973 - Bioactive surface with osteogenic, osteoinductive, anti-inflammatory and anti-fibrotic properties. Reduces peri-implantitis and implant failure risk

Metal surfaces functionalized with flavonoids, cheap antioxidant molecules of natural origin, with demonstrated osteogenic, osteoinductive, anti-inflammatory and anti-fibrotic properties. The same coating promotes both soft and hard tissue integration of dental implants. It is of high interest to use it to avoid peri-implantitis occurrence, thus decreasing implant loss risks, and in periodontal disease treatments.

Key publications:

Gomez-Florit, M.; et al. (2016). Quercitrin-nanocoated titanium surfaces favour gingival cells against oral bacteria. Scientific Reports 6: 22444.
Córdoba, A.; et al. (2015). Bioinspired quercitrin nanocoatings: A fluorescence-based method for its surface quantification, and its effect on stem cell adhesion and differentiation to the osteoblastic lineage. ACS Applied Materials & Interfaces 7 (30): 16857–16864.
Córdoba, A.; et al. (2015). Flavonoid-Modified Surfaces: Multifunctional Bioactive Biomaterials with Osteopromotive, Anti-Inflammatory, and Anti-Fibrotic Potential. Advanced Healthcare Materials 4(4): 540-549.
Gómez-Florit, M.; et al. (2015). Quercitrin for periodontal regeneration: effects on human gingival fibroblasts and mesenchymal stem cells. Scientific Reports 5:16593.
Gómez-Florit, M.; et al. (2014). Identification of quercitrin as potential therapeutic agent for periodontal applications. Journal of Periodontology 85(7):966-74.
Satúe, M.; et al. (2013). Quercitrin and Taxifolin stimulate osteoblast differentiation in MC3T3-E1 cells and inhibit osteoclastogenesis in RAW 264.7 cells. Biochemical Pharmacology 86(10): 1476-1486.

NM_975 - Slippery but osteopromotive surface for temporary implants

Bioactive biomaterial metal surfaces photo-activated with omega-3 polyunsaturated fatty acids (PUFA) combined with vitamins. For use in temporary implants like bone plates, screws and splints used for fracture fixation, that are to be removed after the bone has healed. This surface stimulates bone healing through the biological action of omega-3 PUFA while hindering tissue adherence to the implant surface, making it a so called “slippery implant”.

Key publications:

Petzold, C. et al. (2008) UV-induced chemical coating of titanium surfaces with eicosapentaenoic acid. J Mater Chem,18:5502–5510.
Petzold, C. et al. (2011) In vivo performance of titanium implants functionalized with eicosapentaenoic acid and UV irradiation. J Biomed Mater Res, 96A:83–92.
Petzold, C. et al. (2012) EPA covalently bound to smooth titanium surfaces decreases viability and biofilm formation of Staphylococcus epidermidis in vitro. J Orthop Res, 30 :1384–1390.

NM_977 - Bioactive surface modified with phytate for improving bone integration and decreasing bacterial adhesion

Metallic surfaces covalently coated with phytate, a natural molecule abundant in plant seeds that inhibits bone resorption. This surface shows osteogenic properties and decreases bacterial adhesion.

Key publications:

Córdoba, A.; et al. (2016). Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti–O–P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials & Interfaces 8 (18): 11326-11335.
Arriero, M. M. ; et al. (2012). Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts. Plos One 7 (8): e43187
Arriero, M. M. ; et al. (2012). Differential response of MC3T3-E1 and human mesenchymal stem cells to inositol hexakisphosphate. Cellular Physiology and Biochemistry 30 (4): 974-986

News

17/04/2018

Within the framework of the Initiation Program Export ICEX Next, NuMat Medtech has recieved the support of ICEX co-financed by the FEDER European Fund. The Initiation Program Export ICEX Next purpose is to contribute to the entry of the company to new international markets through the development of commercial actions with industrial partners.

28/10/2016

NuMat Medtech is formed after the merger of Sanifit Medtech and NuMat Biomedical.

01/01/2014

The PHYTECH project coordinated by Numat Biomedical is officially recognized as a Eurostars labelled project.

05/06/2013

Intelligent regenerating bone implants: PHYTECH project. Osseointegration and biocompatibility are the two key qualities on the design and development of new materials for bone implants. This is the work currently developed by the PHYTECH project, with the main objective to develop innovative implants capable to repair and regenerate bone tissue. PHYTECH is a public-private initiative, funded by the INNPACTO Project (granted by the Ministry of Economy and Competitiveness) and it will be developed over the next two years. The total budget is EUR 700.000 and the consortium members are two Spanish biotechnology companies, NuMat Biomedical SL and Laboratoris SANIFIT SL, the Universitat de les Illes Balears (UIB) and the Center for Biomedical Research in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), of the Instituto de Salud Carlos III.

31/12/2012

The Eurostar project NewBone has come to an end, however the development continues!

All
/
2011
/
2010
/
2009
/
2008

20/09/2011

10% of companies receiving Technological Funds from Invest in Spain are biotech companies from the Balearics. Numat Biomedical gets first position in the ranking evaluation of the project among all the proposals in Spain. The project is also funded by the European Regional Development Fund (ERDF) from the European Union.

01/09/2011

Balearic Biotech Scenario in 2011 (see video).

12/10/2010

From Lab Bench to Bedside: traslational research at IUNICS (in Spanish only).

06/06/2010

The Incubator for technology-based enterprizes at ParcBIT supports the development of 52 companies (in Spanish only).

01/06/2010

NuMat Biomedical, finalist for the prize “Emprendedor XXI 2010” in the Balearics.

16/05/2010

The triangle of the biomedical research in the Balearics (in Spanish only).

16/03/2010

Projects with future: development of a synthetic bone graft substitute for dental and orthopedic applications (in Spanish only).

11/12/2009

NuMat Biomedical receives the award “Entrepreneur Women 2009” from the Department of Youth and Equality of the Consell de Mallorca.

10/12/2009

NuMat Biomedical participates in the “I Technological Forum of the Balearic Islands (Forotec)” at ParcBIT, organized by the Directorate-General of Research, Technological Development and Innovation from Ministry of Internal Affairs of the Balearic Islands Government.

04/12/2009

NuMat Biomedical receives the awards “Young Entrepreneur from Mallorca 2009” and “Young Entrepreneur from the Balearics 2009” from the Association of Young Entrepreneurs of the Balearic Islands.

22/10/2009

Numat Biomedical and Blood and Tissue Bank Foundation from the Balearic Islands (FBSTIB) have signed a cooperational agreement to investigate the use of stem cells in bone regeneration.

06/04/2009

New and innovative biomaterials for bone tissue regeneration (in Spanish only).

31/08/2008

Report about Biotech Companies located at ParcBIT (in Spanish only).

27/08/2008

Entrepreneurs and Investors meet to boost the future financial situation at the Balearics (in Spanish only).

Contact

Don’t hesitate to contact us if you wish more information.

Contact

ParcBIT (Balearic Islands Innovation and Technology Park) / Building Europa, 2nd floor
Ctra. Valldemossa km. 7.4
E-07121 Palma de Mallorca
Illes Balears
Spain
info@numat.org